Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1625-1630

  Peng, Hong Hua ^a   Zhang, Yang De ^b   Gong, Lian Sheng ^b   Liu, Wei Dong ^b   Zhang, Yang ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

microRNA 335; Primary gallbladder carcinoma; Prognosis; Real time quantitative RT PCR assay

Indexed keywords

MICRORNA; MICRORNA 335; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GALLBLADDER CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84888155294     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S53030     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56(2):106-130.
2. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196(2):252-264.
3. Balachandran P, Agarwal S, Krishnani N, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006;10(6):848-854.
4. Kim WS, Choi DW, You DD, Ho CY, Heo JS, Choi SH. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14(4):679-687.
5. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell. 2006;125(6):1111-1124.
6. Liu X, Liu L, Xu Q, Wu P, Zue X, Ji A. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther. 2012;12(5):573-580.
7. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6): 590-610.
8. Kono H, Nakamura M, Ohtsuka T, et al. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep. 2013;30(1):17-24.
9. Srivastava K, Srivastava A, Mittal B. Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet. 2010;55(8):495-499.
10. Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun. 2013;430(2):529-534.
11. Shi L, Jiang D, Sun G, et al. miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. J Neurooncol. 2012;110(2): 155-162.
12. Shu M, Zhou Y, Zhu W, et al. microRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Mol Pharmacol. 2012;81(3):292-298.
13. Ronchetti D, Lionetti M, Mosca L, et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008;1:37.
14. Heyn H, Engelmann M, Schreek S, et al. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011;129(12):2797-2806.
15. Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42(2): 411-418.
16. Huang HY, Cheng YY, Liao WC, et al. SOX4 transcriptionally regulates multiple SEMA3/plexin family members and promotes tumor growth in pancreatic cancer. PLoS One. 2012;7(12):e48637.
17. Yan Z, Xiong Y, Xu W, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7(7):e40037.
18. Xu Y, Zhao F, Wang Z, et al. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 2012;31(11):1398-1407.
19. AJCC cancer staging manual, 6th edition. New York, NY, USA: Springer, 2002.
20. Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39(2):331-342.
21. Lee HK, Cho MS, Kim TH. Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Oncol. 2012;10:224.
22. Jiang W, Chen X, Liao M, et al. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep. 2012;2:282.
23. Vega AB, Pericay C, Moya I, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320-326.
24. Zhu K, Pan Q, Zhang X, et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis. 2013;34(9):2071-2079.
25. Chai S, Ma S. Clinical implications of microRNAs in liver cancer stem cells. Chin J Cancer. 2013;32(8):419-426.
26. Yu G, Li H, Wang X, et al. MicroRNA-19a targets tissue factor to inhibit colon cancer cells migration and invasion. Mol Cell Biochem. 2013;380(1-2):239-247.
27. Bovell L, Putcha B, Samuel T, Manne U. Clinical implications of microRNAs in cancer. Biotech Histochem. 2013;88(7):388-396.
28. Xiong SW, Lin TX, Xu KW, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res. 2013;19(3): 529-537.
29. Yang H, Zhang C, Lu YX, et al. [Construction of has-miR-335 lentiviral vector and verification of the target gene of miR-335.] Nan Fang Yi Ke Da Xue Xue Bao. 2012;32(3):306-311. Chinese.
30. Tomé M, López-Romero P, Albo C, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ. 2011;18(6):985-995.
31. Jiang J, Sun X, Wang W, et al. Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol. 2012;29(5):3472-3477.